2020
Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging
Matuskey D, Tinaz S, Wilcox KC, Naganawa M, Toyonaga T, Dias M, Henry S, Pittman B, Ropchan J, Nabulsi N, Suridjan I, Comley RA, Huang Y, Finnema SJ, Carson RE. Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging. Annals Of Neurology 2020, 87: 329-338. PMID: 31953875, PMCID: PMC7065227, DOI: 10.1002/ana.25682.Peer-Reviewed Original ResearchConceptsSubstantia nigraParkinson's diseaseNormal controlsSynaptic changesPositron emission tomographic imagingSynaptic vesicle glycoprotein 2AParkinson's disease groupParkinson's disease subjectsEmission tomographic imagingPrimary brain areasAnn NeurolPostmortem autoradiographyBilateral diseaseNonmotor symptomsSynaptic lossNeuronal alterationsRelevant cortical areasStriatal dopamineBrainstem nucleiDisease groupDopamine neuronsLocus coeruleusCortical areasRed nucleusDopamine system
2019
A single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers
Finnema SJ, Rossano S, Naganawa M, Henry S, Gao H, Pracitto R, Maguire RP, Mercier J, Kervyn S, Nicolas J, Klitgaard H, DeBruyn S, Otoul C, Martin P, Muglia P, Matuskey D, Nabulsi NB, Huang Y, Kaminski RM, Hannestad J, Stockis A, Carson RE. A single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. Epilepsia 2019, 60: 958-967. PMID: 30924924, PMCID: PMC6532410, DOI: 10.1111/epi.14701.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnticonvulsantsCarbon RadioisotopesFemaleHealthy VolunteersHumansInhibitory Concentration 50Injections, IntravenousLevetiracetamMagnetic Resonance ImagingMaleMembrane GlycoproteinsNerve Tissue ProteinsNeuroimagingPositron-Emission TomographyProtein BindingPyrrolidinonesConceptsSynaptic vesicle glycoprotein 2AIntravenous brivaracetamHours postdoseBrain penetrationHealthy volunteersDaily oral dosingPositron emission tomography studyFurther clinical studiesEmission tomography studiesPlasma concentration relationshipPositron emission tomography (PET) tracerEmission tomography tracerVivo animal studiesAcute seizuresAntiepileptic drugsTherapeutic dosesCohort 2Oral dosingCohort 1Clinical studiesCohort 3LevetiracetamAnimal studiesRelevant dosesBrivaracetam
2005
Serotonin alterations in anorexia and bulimia nervosa: New insights from imaging studies
Kaye W, Frank G, Bailer U, Henry S, Meltzer C, Price J, Mathis C, Wagner A. Serotonin alterations in anorexia and bulimia nervosa: New insights from imaging studies. Physiology & Behavior 2005, 85: 73-81. PMID: 15869768, DOI: 10.1016/j.physbeh.2005.04.013.Peer-Reviewed Original ResearchConceptsBulimia nervosaAnorexia nervosaBody image distortionAge of onsetParietal cortical regionsHomogenous presentationSerotonin alterationsLimbic structuresSerotonin pathwayGender distributionCortical regionsBrain functionNew pharmacologyNervosaFood consumptionIllnessSymptomsRecent brainAlterationsRecent studiesPsychotherapy approachesBehavioral inhibitionAnxietyFeeding behaviorHedonic aspectsRelationship of a 5-HT transporter functional polymorphism to 5-HT1A receptor binding in healthy women
Lee M, Bailer U, Frank G, Henry S, Meltzer C, Price J, Mathis C, Putnam K, Ferrell R, Hariri A, Kaye W. Relationship of a 5-HT transporter functional polymorphism to 5-HT1A receptor binding in healthy women. Molecular Psychiatry 2005, 10: 715-716. PMID: 15940302, DOI: 10.1038/sj.mp.4001680.Peer-Reviewed Original Research